This invention relates to the design and function of a compressible valve replacement prosthesis, collared or uncollared, which can be deployed into a beating heart without extracorporeal circulation using a transcatheter delivery system. The design as discussed focuses on the deployment of a device via a minimally invasive fashion and by way of example considers a minimally invasive surgical procedure preferably utilizing the intercostal or subxyphoid space for valve introduction. In order to accomplish this, the valve is formed in such a manner that it can be compressed to fit within a delivery system and secondarily ejected from the delivery system into the annulus of a target valve such as a mitral valve or tricuspid valve.

Encasement structures and methods of customizing patient drug delivery profiles using an encasement structure are described herein. Encasement structures can be configured to receive an implantable medical device and physicians can implant the medical devices within the encasement structures. Encasement structures can include at least one sheet of a bioscaffold material and one or more depots. depots can be configured to release an active agent, such as an antibiotic, to the medical device within the encasement structure and/or the surrounding tissue. The depots can be insertable into or integrated with the at least one sheet of bioscaffold material.

This invention relates to the design and function of a compressible valve replacement prosthesis, collared or uncollared, which can be deployed into a beating heart without extracorporeal circulation using a transcatheter delivery system. The design as discussed focuses on the deployment of a device via a minimally invasive fashion and by way of example considers a minimally invasive surgical procedure preferably utilizing the intercostal or subxyphoid space for valve introduction. In order to accomplish this, the valve is formed in such a manner that it can be compressed to fit within a delivery system and secondarily ejected from the delivery system into the annulus of a target valve such as a mitral valve or tricuspid valve.

Described are embodiments of a multilaminate or multiple layer implantable surgical graft with an illustrative graft comprising a remodelable collagenous sheet material, the graft including one or more interweaving members to stitch together the graft to help prevent the layers from delaminating or separating during handling and the initial stages of remodeling. The interweaving members may comprise lines of suture, thread, individual stitches, strips of material, etc. that are woven through the layers of biomaterial in a desired pattern. In one embodiment, the interweaving members comprise a pharmacologically active substance, such as a drug, growth factors, etc. to elicit a desired biological response in the host tissue. In another embodiment, the graft further comprises a reinforcing material, such as a synthetic mesh, within the layers of remodelable biomaterial and stitched together by one or more interweaving members.

An antibacterial medical biomaterial includes an acellular small intestinal submucosal matrix material, an antibacterial gel layer located on a surface of the acellular small intestinal submucosal matrix material, and an absorbable fiber layer located on a surface of the antibacterial gel layer. Sulfadiazine silver is on the surface of the acellular small intestinal submucosal matrix material and/or within the acellular small intestinal submucosal matrix material. An absorbable fiber layer to which the sulfadiazine silver is attached, wherein the content of sulfadiazine silver in the absorbable fiber is 1 wt. %˜2 wt. %. The medical biomaterial is usable as an external medicine for treating wound infections relayed by burns or wounds, and for reducing the incidence of infection by using a conventional central venous catheter with a sulfadiazine silver antibacterial coating, so that the medical biomaterial loaded with sulfadiazine silver also has antibacterial activity consistent with sulfadiazine silver.

This invention relates to the design and function of a compressible valve replacement prosthesis, collared or uncollared, which can be deployed into a beating heart without extracorporeal circulation using a transcatheter delivery system. The design as discussed focuses on the deployment of a device via a minimally invasive fashion and by way of example considers a minimally invasive surgical procedure preferably utilizing the intercostal or subxyphoid space for valve introduction. In order to accomplish this, the valve is formed in such a manner that it can be compressed to fit within a delivery system and secondarily ejected from the delivery system into the annulus of a target valve such as a mitral valve or tricuspid valve.

Tissue prostheses having a base structure and a physiological sensor system. The tissue prostheses are adapted and configured to induce remodeling of damaged tissue and regeneration of new tissue and concurrently detect and monitor physiological characteristics when implanted in the subject.

The present disclosure provides methods of bioengineering sphincters having autologous smooth muscle cells isolated from human internal anal sphincter and autologous enteric neurospheres (neural progenitor cells) isolated from human small intestine (jejunum). The isolated neural progenitor cells and smooth muscle cells are co -cultured using dual layered hydrogels and allowed to form circular, intrinsically innervated internal anal sphincter constructs. Such innervated internal anal sphincter constructs, bioengineered internal anal sphincter constructs are useful as additive implants in the treatment of fecal incontinence.

Sheet structures for regenerating damaged or diseased mammalian tissue that are formed from acellular dermal mammalian tissue. The acellular dermal mammalian tissue includes extracellular matrix (ECM) and a supplemental bioactive component. The supplemental bioactive component can comprise a nucleic acid, such as RNA, and/or a cell, such as an embryonic stem cell. The sheet structures induce angiogenesis and, thereby, regeneration of new mammalian tissue.

The invention is a biodegradable polymer composition comprising a particulate biodegradable polymer, particulate extracellular matrix (ECM) derived from a mammalian tissue source, a therapeutic component that abates growth of bacteria and a liquid medium. The biodegradable polymer can change quality upon contact with a physiological parameter, such as temperature or pH that causes, for example, a liquid polymer to gel or harden. The polymer composition is adapted to induce regeneration of tissue in vivo.